KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Assets Average (2016 - 2025)

Historic Assets Average for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to $1.4 billion.

  • Supernus Pharmaceuticals' Assets Average rose 540.26% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 540.26%. This contributed to the annual value of $1.3 billion for FY2024, which is 1122.2% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Assets Average of $1.4 billion as of Q3 2025, which was up 540.26% from $1.4 billion recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Assets Average high stood at $1.7 billion for Q1 2023, and its period low was $1.3 billion during Q4 2023.
  • Its 5-year average for Assets Average is $1.5 billion, with a median of $1.5 billion in 2021.
  • In the last 5 years, Supernus Pharmaceuticals' Assets Average skyrocketed by 2814.28% in 2021 and then crashed by 2611.54% in 2024.
  • Supernus Pharmaceuticals' Assets Average (Quarter) stood at $1.6 billion in 2021, then grew by 4.67% to $1.7 billion in 2022, then decreased by 24.53% to $1.3 billion in 2023, then grew by 5.77% to $1.4 billion in 2024, then grew by 3.37% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.4 billion during Q1 2025.